Varlamova Elena G, Burmistrov Dmitry E, Gudkov Sergey V, Rogachev Vladimir V, Turovsky Egor A
Institute of Cell Biophysics, The Russian Academy of Sciences, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", 142290, Pushchino, Russia.
Prokhorov General Physics Institute, The Russian Academy of Sciences, 119991, Moscow, Russia.
Biochem Biophys Res Commun. 2025 Sep 8;778:152364. doi: 10.1016/j.bbrc.2025.152364. Epub 2025 Jul 16.
To date, there is no effective and at the same time less toxic therapeutic option for patients with hepatocellular carcinoma, which is the second cause of death in the world. Known drugs for the treatment of cancer lead to the development of primary or acquired resistance and progression of the disease. One of the well-known first-line drugs for the treatment of liver and kidney cancer is So. However, it has poor solubility, the need for high doses with the resulting complications for healthy tissues and organs. In the last decade, the anticancer properties of selenium nanoparticles have been actively studied, including for the treatment of hepatocellular carcinoma. Therefore, in this work, a comprehensive comparative analysis of the anticancer properties of So and selenium nanoparticles is carried out on a model of thioacetamide-induced hepatocellular carcinoma in mice. The results of the analysis showed that selenium nanoparticles, along with So, have pronounced anti-inflammatory properties and are involved in the activation of protective mechanisms by suppressing tumor markers and HCC-associated signaling pathways. Based on the results of the comparative analysis, we identified some advantages in the effectiveness of selenium nanoparticles in mitigating the effects of HCC compared to So.
迄今为止，对于作为全球第二大致死原因的肝细胞癌患者，尚无有效且毒性较小的治疗选择。已知的癌症治疗药物会导致原发性或获得性耐药以及疾病进展。索拉非尼（So）是治疗肝癌和肾癌的著名一线药物之一。然而，它的溶解度较差，需要高剂量使用，从而对健康组织和器官产生并发症。在过去十年中，人们积极研究了硒纳米颗粒的抗癌特性，包括用于治疗肝细胞癌。因此，在这项工作中，我们在硫代乙酰胺诱导的小鼠肝细胞癌模型上对索拉非尼和硒纳米颗粒的抗癌特性进行了全面的比较分析。分析结果表明，硒纳米颗粒与索拉非尼一样，具有显著的抗炎特性，并通过抑制肿瘤标志物和肝癌相关信号通路参与激活保护机制。基于比较分析的结果，我们确定了与索拉非尼相比，硒纳米颗粒在减轻肝癌影响方面有效性的一些优势。
